UNSPSC 51343815: Lamivudine/stavudine

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, STAVUDINE, has US FDA Unique Ingredient Identifier of BO9LE4QFZF.

UNSPSC 51343815 Lamivudine/stavudine is a Commodity code, but the recent state and local opportunities posted under this code do not align with its pharmaceutical-product scope. Of the ten records in the source, only two involve actual pharmaceutical procurement: Dane County's RFP for comprehensive pharmaceutical services at a long-term care facility (Badger Prairie Health Care Center), and West Texas Centers for Mental Health and Mental Retardation's RFP for prescription and pharmacy services across 35 service sites. The remaining eight records—a Notice of Intent to Single Source a mobile EMS drug-calculation application (Collier County), a procurement conference networking event (Clay County), an aquatic center operational partnership RFP (City of Palm Bay), a pharmacy benefits program network qualification notice (District of Columbia), a naloxone distribution center letter of interest (Washington County, Oregon), an on-call technical services bid list (City of Owensboro, Kentucky), a Group Purchasing Organization membership proposal (San Mateo County), and a drug standards procurement for forensic analysis (Pinellas County)—fall outside the code's nominal scope of antiretroviral combination medications. The code shows little relevant recent activity for antiretroviral procurement specifically.

No state or local government solicitations in the source data seek Lamivudine/stavudine or related antiretroviral medications as a standalone or primary procurement line item. The two pharmaceutical-services opportunities (Dane County and West Texas Centers) involve full-service pharmacy operations, dispensing, and consultation rather than procurement of specific drug products. Dane County's RFP for Badger Prairie Health Care Center (response due October 22, 2026) encompasses medication purchasing and dispensing for a long-term care facility with current annual pharmaceutical spending of $125,000, a local-vendor preference of 5 points for Dane County residents, and a five-year contract term. West Texas Centers' RFP for prescription and pharmacy services (response due August 21, 2026) covers over 7,000 individuals across 35 sites in 23 counties with utilization data from May–July 2026 showing 15,187 medication claims, though the source does not specify antiretroviral volumes or procurement priorities. Neither opportunity explicitly names Lamivudine/stavudine or other antiretrovirals as priority medications. A business development professional evaluating this code should note that the taxonomy mismatch suggests either data-entry inconsistency in the recent postings or that state and local government procurement of this specific antiretroviral combination is currently inactive at the level captured in the source.